# Successful Pharmacologic Treatment of Self-Bloodletting with Factitious Chronic Anemia (Lasthénie de Ferjol Syndrome) with High-Dose Serotonergic Medication: A Case Report

**Authors:** Stefan Mestermann, Laura Rudtke, Razvan-Marius Brazdis, Thanos Tsaktanis, Johannes Kornhuber, Norbert Thürauf

PMC · DOI: 10.3390/bs14030237 · 2024-03-14

## TL;DR

A rare case shows that high-dose serotonergic medications can effectively treat self-bloodletting and related anemia in a psychiatric patient.

## Contribution

This case report suggests high-dose clomipramine or escitalopram may be effective in treating self-bloodletting and Lasthénie de Ferjol syndrome.

## Key findings

- High-dose clomipramine reduced self-bloodletting and suicidal thoughts in a patient with Lasthénie de Ferjol syndrome.
- Escitalopram also effectively decreased and stopped the patient's self-bloodletting urges after clomipramine was discontinued.
- Serotonergic antidepressants may be crucial in treating this rare psychiatric condition.

## Abstract

Self-induced bloodletting (SBL) is a very rare form of self-injury (SI) seen primarily in adolescents and young adults with personality and eating disorders. It can result in complications like malaise, fatigue, or iron-deficiency anemia (Lasthénie de Ferjol syndrome, LFS), and poses a risk of accidental death or suicide. The condition often goes undetected due to patient concealment. There is no specific treatment established, and pharmacological strategies remain uncertain. We discuss the case of a 22-year-old female patient treated at our Psychiatry and Psychotherapy Department following a suicide attempt via SBL. She self-administered a venous cannula, losing 1.5 L of blood. Diagnosed with iron-deficiency anemia (LFS), she was initially treated with mirtazapine, risperidone, lithium, and later off-label high-dose clomipramine (300 mg/d). Clomipramine significantly reduced her SBL and suicidal thoughts, and her hemoglobin levels re-normalized under iron-substitution therapy. Despite improvement and later discharge, she attempted suicide by SBL again three months later, having stopped clomipramine due to adverse side effects. High-dose escitalopram was administered, leading to a decrease and eventual cessation of her SBL urges. This case demonstrates that patients with SBL/LFS can benefit from high-dose clomipramine or escitalopram. Despite its rarity, the consideration of high-dose serotonergic antidepressants is crucial in psychiatric diagnostics and treatment for patients affected by SBL/LFS.

## Linked entities

- **Chemicals:** clomipramine (PubChem CID 2801), escitalopram (PubChem CID 146570), mirtazapine (PubChem CID 4205), risperidone (PubChem CID 5073), lithium (PubChem CID 28486)
- **Diseases:** iron-deficiency anemia (MONDO:0001356)

## Full-text entities

- **Diseases:** iron-deficiency anemia (MESH:D018798), Lasthenie de Ferjol Syndrome (MESH:D005862), death (MESH:D003643), Factitious Chronic Anemia (MESH:D005162), fatigue (MESH:D005221), SI (MESH:D012652), LFS (MESH:D016864), psychiatric (MESH:D001523), personality (MESH:D010554), eating disorders (MESH:D001068)
- **Chemicals:** Serotonergic Medication (-), risperidone (MESH:D018967), escitalopram (MESH:D000089983), mirtazapine (MESH:D000078785), Clomipramine (MESH:D002997), iron (MESH:D007501), lithium (MESH:D008094)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC10967711